-
Mashup Score: 7
The US Food and Drug Administration has withdrawn its emergency use authorisation for the covid-19 antibody drug Evusheld, citing data showing that the treatment is unlikely to be effective against the XBB.1.5 subvariant of omicron now dominant in the United States. Evusheld, manufactured by AstraZeneca, is a combination of two long acting antibodies, tixagevimab and cilgavimab. It is given as…
Source: The BMJCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0FDA Update: Evusheld Not Currently Authorized For Emergency Use in U.S. - American College of Cardiology - 1 year(s) ago
The U.S. Food and Drug Administration (FDA) on Jan. 26 announced that Evusheld (tixagevimab co-packaged with cilgavimab) is not currently authorized for emergency use against COVID-19 in the U.S. until further notice by the Agency. The FDA revised the scope of the Emergency Use Authorization (EUA) for Evusheld “to limit the use of EVUSHELD for pre-exposure prophylaxis of COVID-19 in the United…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#FDAUpdate: @US_FDA has announced #Evusheld is not currently authorized for emergency use in the US against #COVID19 as less than 10% of circulating variants causing infection are susceptible to the product. Learn more: https://t.co/mnV00LVIyU
-
-
Mashup Score: 0FDA Withdraws EUA for Evusheld - 1 year(s) ago
The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.
Source: OncLiveCategories: Infectious Disease, Latest HeadlinesTweet-
The #FDA withdrew its Emergency Use Authorization for tixagevimab and cilgavimab #Evusheld in order to limit its use to when the combined frequency of non-susceptible #SARSCoV2 variants nationally is less than or equal to 90%. #IDtwitter #Medtwitter https://t.co/CdlseFtWW7
-
-
Mashup Score: 0
Evusheld is no longer authorized for use to help prevent COVID-19 in the United States “until further notice,” due to a lack of protection against dominant variants, according to new guidance issued by the FDA.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: #Evusheld is no longer authorized to prevent #COVID19. Including a new perspective from @LCalabreseDO https://t.co/EbtnoaQ7eM
-
-
Mashup Score: 0FDA Withdraws EUA for Evusheld - 1 year(s) ago
The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.
Source: OncLiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Breakingnews The #FDA does not want clinicians utilizing #Evusheld as newer, circulating #COVID19 strains and efficacy against them is limited. https://t.co/CdlseFtWW7 https://t.co/oHl11PV70E
-
-
Mashup Score: 0
Evusheld is no longer authorized for use to help prevent COVID-19 in the United States “until further notice,” due to a lack of protection against dominant variants, according to new guidance issued by the FDA.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Citing reduced effectiveness against circulating variants, the @US_FDA has issued guidance stating that #Evusheld is no longer authorized #MedTwitter https://t.co/EbtnoaQ7eM
-
-
Mashup Score: 9
Evusheld is the latest antibody therapy to be rendered ineffective by coronavirus mutations.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
The FDA on Thursday withdrew the authorization of #Evusheld, the latest antibody therapy to be rendered ineffective by the mutations the virus has picked up. https://t.co/ZKMrtCjMWN
-
-
Mashup Score: 0
Evusheld is no longer authorized for use to help prevent COVID-19 in the United States “until further notice,” due to a lack of protection against dominant variants, according to new guidance issued by the FDA.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Evusheld is no longer authorized for use to help prevent #COVID19 in the United States “until further notice,” due to a lack of protection against dominant variants https://t.co/EbtnoaQ7eM
-
-
Mashup Score: 4Biden officials search for backup for key Covid therapy for immunocompromised people - 2 year(s) ago
Biden officials are bracing for the prospect that the sole preventive Covid treatment for immunocompromised people, Evusheld, could soon be ineffective.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
News that AstraZeneca’s #Evusheld is not effective against a steadily climbing coronavirus strain has sent health officials racing to game out other antibody options and convene a meeting with patient groups. https://t.co/SqLtwvThqp via @owermohle
-
-
Mashup Score: 0Evusheld, aggressive therapy may reduce COVID-19 severity in patients on B-cell depletion - 2 year(s) ago
Pre-exposure prophylaxis with Evusheld, combined with aggressive outpatient treatment, may reduce COVID-19 severity in patients with immune-mediated inflammatory disease on B-cell depletion, according to a letter published in RMB Open. “It is well-known that this group of patients is at very high risk for severe COVID and death, even when fully vaccinated, and it has become clear that more
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: “Our data suggest that #Evusheld pre-exposure prophylaxis in combination with aggressive outpatient treatment of #COVID19 is likely effective in lowering risk of severe COVID in this vulnerable group,” @CCalabreseDO told Healio. https://t.co/Vrb7JhvbGq
-
The US Food and Drug Administration has withdrawn its emergency use authorisation for the covid-19 antibody drug #Evusheld, citing data showing that the treatment is unlikely to be effective against the XBB.1.5 subvariant of omicron now dominant in the US https://t.co/OdGaviMaPm